In The Lancet Oncology, Josep Tabernero and colleagues 1 report the final analysis of the JACOB trial, which tested the efficacy and safety of pertuzumab (a monoclonal antibody targeting HER2 receptors) combined with trastuzumab and chemotherapy in previously untreated patients with HER2-positive metastatic gastric or gastrooesophageal junction cancer. JACOB was the first trial to investigate a dual HER2 blockade in metastatic gastric cancer; unfortunately, no significant improvement in overall survival was observed in the group treated with the dual-HER2 targeted combination.
Pertuzumab therapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer
Roviello, Giandomenico;Generali, Daniele
2018-01-01
Abstract
In The Lancet Oncology, Josep Tabernero and colleagues 1 report the final analysis of the JACOB trial, which tested the efficacy and safety of pertuzumab (a monoclonal antibody targeting HER2 receptors) combined with trastuzumab and chemotherapy in previously untreated patients with HER2-positive metastatic gastric or gastrooesophageal junction cancer. JACOB was the first trial to investigate a dual HER2 blockade in metastatic gastric cancer; unfortunately, no significant improvement in overall survival was observed in the group treated with the dual-HER2 targeted combination.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Pertuzumab therapy for HER2.pdf
Accesso chiuso
Tipologia:
Documento in Versione Editoriale
Licenza:
Copyright Editore
Dimensione
569.84 kB
Formato
Adobe PDF
|
569.84 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
